肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Brit J Cancer：癌症患者COVID-19死亡风险

2021-08-17 网络 网络

癌症死亡风险Covid-19
关注

该研究结果进一步证实了男性和亚洲癌症患者、血液系统恶性肿瘤或诊断2年以上的癌症患者COVID-19的死亡风险增加。在为癌症患者做临床决定时，应考虑这些因素。

近日，肿瘤学领域权威杂志British Journal of Cancer上发表了一篇研究文章，研究人员旨在明确与COVID-19死亡相关的癌症患者特征。


研究人员使用了2020年2月29日至7月31日期间在盖伊癌症中心和国王学院医院就诊的严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)逆转录聚合酶链反应咽拭子阳性的所有癌症患者的数据，并进行Cox比例风险回归以确定哪些因素与COVID-19死亡率相关。

该研究纳入306例SARS-CoV-2阳性的肿瘤患者。71%的患者为轻度/中度COVID-19，29%的患者为重度COVID-19。72例(24%)患者死于COVID-19，其中35例患者死亡时间小于7天。男性[风险比(HR):1.97(95%置信区间(CI):1.15-3.38)]、亚裔[3.42(1.59-7.35)]、血液系统癌症[2.03(1.16-3.56)]和癌症诊断>2-5年[2.81(1.41-5.59)]或≥5年与死亡率增加相关。

年龄>60岁和c反应蛋白(CRP)升高也与COVID-19死亡相关。血液系统癌症、诊断时伴有呼吸困难和CRP升高提示癌症患者(确诊后7天内)发生COVID-19相关的早期死亡。
 
由此可见，该研究结果进一步证实了男性和亚洲癌症患者、血液系统恶性肿瘤或诊断2年以上的癌症患者COVID-19的死亡风险增加。在为癌症患者做临床决定时，应考虑这些因素。

原始出处：

Beth Russell.et al.Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London.Brit J Cancer.2021.https://www.nature.com/articles/s41416-021-01500-z

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-19 quxin068

    #死亡风险#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-19 zgwhgch

    #癌症患者#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 tanxingdoctor

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 智慧药

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 涂涂0518

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 Linsanity

    学到了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1256124, encodeId=d67512561249c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289733, encodeId=11241289e33d1, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Aug 19 14:09:07 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008980, encodeId=3867100898024, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed Aug 18 10:38:37 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008929, encodeId=535710089297c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 18 09:12:55 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008917, encodeId=99f8100891eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 18 08:54:49 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008886, encodeId=1116100888699, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40e65325688, createdName=Linsanity, createdTime=Wed Aug 18 02:01:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008870, encodeId=d7a910088e0d8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 00:08:00 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-08-18 小火龙111

    nice

    0

相关资讯

Nature Medicine：重磅！晚期癌症患者100%治疗反应！88%完全缓解！双特异性靶点CAR-T疗法1期临床试验结果公布

再给CAR-T细胞一个识别的靶点，双倍识别，可以更好地发挥治疗效果.

Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布

癌症细胞治疗，属于免疫治疗，通过将自体或异体免疫细胞在体外进行改造后回输到病人体内，从而增强其对癌细胞的杀伤作用，进而治疗癌症。目前癌症细胞治疗包括 CAR-T、TCR-T、CAR-NK、TIL、CT

8年内3次患癌成三重癌，光动力治疗让他重获生命之“光”

先后3次患上癌症是种什么样的体验？57岁的东北林先生（化名）似乎有些倒霉，他2012年患上喉癌，2018年确诊下咽部肿瘤，2020年底又在体检时发现食管早癌。

Lightbeam Health Solutions宣布与基因检测公司Ambry Genetics建立合作伙伴关系

CARE Program™将直接与Lightbeam整合，提供风险评估和检测服务，以检测遗传性疾病风险的上升情况

PLOS Med ：体内脂肪过多或会增加癌症风险

脂肪量和消化道癌症之间的联系可能是由脂肪类食物中致癌物质的摄入量增加，或脂肪组织的增加增加了消化道炎症。

Cell Reports：NAD+增强癌症免疫治疗效果

2021年8月10日，上海科技大学生命科学和技术学院范高峰教授和王皞鹏教授作为共同通讯作者，在 Cell Reports 期刊在线发表了题为：NAD+ supplement potentiates t